Announcement



19 October 2017

PROMISIA INTEGRATIVE LIMITED - THIRD QUARTER SALES UPDATE

The Directors of Promisia Integrative Limited (NZX: PIL) advise that sales for the third quarter ended 30 September 2017 were \$516,336. Sales year to date for 2017 are \$1,832,416, up 1.25% compared with the same period in 2016.

The launch of Arthrem[®] in NSW, Australia, and the launch of Artevite[®] (the new dog joint supplement) in the New Zealand market have commenced with the company's marketing and distribution agents, in both countries, establishing sales channels for these products. Television advertising of Arthrem[®] in NSW and Artevite[®] in New Zealand will commence in early 2018.

An independent report shows that Arthrem retained its place as the number one joint supplement in New Zealand pharmacies in dollar terms for the month of September 2017 and was the number two single selling product in New Zealand pharmacies in dollar terms for the month of September 2017.

For further information please contact Mr Stephen Underwood, Chairman on 027 499 3387.

ENDS

Promisia Integrative Limited (NZX:PIL) is a company focused on developing and marketing unique therapeutic natural products with proven safety and efficacy from robust data. Our goal is to add scientific methodology and validity to an industry that is often perceived as unscientific.

DDI: +64 4 499 5563 E: <u>info@promisia.com</u> W: promisia.com Level 4, 22 Panama Street PO Box 25396, Wellington New Zealand 6146